The US FTC files an amicus brief arguing that a company has used unlawful strategies to delay the entry of a generic-brand drug into the market for the treatment of Parkinson’s disease (Sage Chemical / TruPharma / Supernus Pharmaceutical)

FTC Files Amicus Brief in Sage Chemical vs. Supernus Pharmaceutical Supporting Competition in the Market for Drug Used to Treat Advanced Parkinson’s Disease* The Federal Trade Commission filed a brief as Amicus Curiae in the U.S. District Court for the District of Delaware in a case related to Sage Chemical Inc. and its marketing partner TruPharma, LLC’s efforts to sell a lower-cost alternative to Apokyn. Apokyn is an

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.